Findings from preclinical research26 showed that GNG4 could be used as a potential biomarker to predict the response of immunotherapy in bladder cancer, implying that GNG4 may be a broad‐spectrum therapeutic target. This evidence concerns the gene GNG4 and urinary bladder carcinoma.